L'intérêt à découvert pour iShares Ethereum Trust - iShares Ethereum Trust ETF donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de iShares Ethereum Trust - iShares Ethereum Trust ETF. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

iShares Ethereum Trust - iShares Ethereum Trust ETF (NASDAQ:ETHA) Stock, Rapport sur les intérêts à découvert

iShares Ethereum Trust - iShares Ethereum Trust ETF

Ethan Allen Interiors Inc

Classover Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDZ#NASDAQ">KIDZ</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDZW#NASDAQ">KIDZW</a>) ("Classover" or the "Company"), a leading provider of live, interactive online learning, today provided an update on its Solana ("SOL") treasury holdings. As of July 21, 2025, the Company holds approximately 57,131 SOL tokens, representing a total market value of approximately $11.27 million, based on a current per-token price of $197.26. The aggregate purchase price for these holdings was approximately $8.55 million, reflecting an average cost basis of $149.70 per SOL, inclusive of staking rewards.
Classover recently entered into two previously announced financing facilities: a $400 million equity purchase agreement and a $500 million senior secured convertible note investment. A substantial portion of the proceeds from these facilities is intended to be allocated toward continued SOL acquisitions.
These transactions are expected to provide enhanced financial flexibility and capital access to expand the Company's Solana-based treasury strategy. With the ability to draw on these facilities as conditions permit, Classover is well-positioned to accelerate SOL accumulation and further strengthen its balance sheet.
Classover continues to expand on its long-term strategic vision of integrating digital assets into its capital allocation framework, leveraging blockchain infrastructure to drive innovation, improve operational efficiency, and create lasting value for shareholders.
However, the price of SOL has historically been subject to dramatic price fluctuations and is highly volatile. There can be no assurance that the per-token price of SOL will not fall substantially, which could adversely affect our business, our financial condition and results of operations, and our market value.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

Markets

KIDZ

KIDZW

Classover Holds ~57,131 SOL Tokens, Reporting $11.27M In Solana Holdings; Plans Further Acquisitions Using $900M In Financing Facilities

WIIM

SBET

SharpLink Gaming shares are trading higher after the company provided updates on its growing Ethereum holdings.

Barclays analyst Nicholas Campanella maintains PG&amp;E (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCG#NYSE">PCG</a>) with a Overweight and lowers the price target from $22 to $20.

Price Target

Analyst Ratings

Barclays Maintains Overweight on PG&E, Lowers Price Target to $20

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>TD Cowen analyst Kevin Kopelman initiated coverage on Royal Caribbean Cruises Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) with a Buy rating and announced a price target of $405. Royal Caribbean shares closed at $346.47 on Monday. <a href="https://www.benzinga.com/quote/RCL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>TD Cowen analyst Kevin Kopelman initiated coverage on Norwegian Cruise Line Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) with a Buy rating and announced a price target of $31. Norwegian Cruise Line shares closed at $23.19 on Monday. <a href="https://www.benzinga.com/quote/NCLH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>TD Cowen analyst Kevin Kopelman initiated coverage on Carnival Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) with a Buy rating and announced a price target of $36. Carnival shares closed at $29.79 on Monday. <a href="https://www.benzinga.com/quote/CCL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>TD Cowen analyst Tyler Van Buren initiated coverage on IDEAYA Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDYA#NASDAQ">IDYA</a>) with a Buy rating. IDEAYA Biosciences shares closed at $21.81 on Monday. <a href="https://www.benzinga.com/quote/IDYA/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying RCL stock? Here&#8217;s what analysts think:
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="595" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22083533/image-305-1024x595.png" alt="" class="wp-image-995352" style="width:621px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22083533/image-305-1024x595.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22083533/image-305-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22083533/image-305-768x447.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/22083533/image-305.png 1111w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46517205/top-2-financial-stocks-that-may-plunge-this-month">Top 2 Financial Stocks That May Plunge This Month</a> </li>
</ul>
Photo via Shutterstock

Initiation

Pre-Market Outlook

Trading Ideas

IDYA

NCLH

This Royal Caribbean Cruises Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday

Benchmark analyst Daniel Kurnos maintains Magnite (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNI#NASDAQ">MGNI</a>) with a Buy and raises the price target from $24 to $30.

MGNI

Benchmark Maintains Buy on Magnite, Raises Price Target to $30

Strategic Partnership Strengthens Reborn's Presence in the Caucasus Region and Aligns with Growing Regional Business Confidence
BREA, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Reborn Coffee Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REBN#NASDAQ">REBN</a>), a leader in the specialty coffee market, today announced it has signed a strategic licensing agreement with The Arjomand Group and IG International, officially marking Reborn's expansion into the Republics of Georgia and Armenia.
The agreement grants IG International exclusive rights to develop and operate Reborn Coffee-branded locations across both Georgia and Armenia, under the framework of a regional licensing partnership facilitated by The Arjomand Group. The move reflects Reborn's ongoing international expansion strategy and positions the brand at the center of two emerging markets with growing consumer demand and increased alignment with European economic standards.

REBN

Reborn Coffee Signs Strategic Licensing Agreement With Arjomand Group And IG International, Officially Marking Reborn's Expansion Into Republics Of Georgia And Armenia

Pagaya Technologies shares are trading lower after the company announced a proposal for a $450 million senior notes offering.

Earnings

Earnings Beats

HomeTrust Bancshares Q2 EPS $1.00 Beats $0.78 Estimate, Adj. Sales $53.34M Beat $50.70M Estimate

Obtaining the payment rates marks a key milestone in gaining broad access to Medicare reimbursement.
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.cdio.ai%2F&amp;esheet=54294186&amp;newsitemid=20250722262254&amp;lan=en-US&amp;anchor=Cardio+Diagnostics+Holdings%2C+Inc.&amp;index=1&amp;md5=298bd595c2aecc63eb9063007bd10e7c">Cardio Diagnostics Holdings, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>), an AI-powered precision cardiovascular medicine company, today announced that the Centers for Medicare and Medicaid Services (CMS), through the MolDX program, has issued preliminary gapfill payment rates of $350 for Epi+Gen CHD&#x2122; and $684.76 for PrecisionCHD&#x2122;. A ‘gapfill' payment rate means that pricing is determined by each Medicare contractor, including MolDX, based on cost data from Cardio Diagnostics.
These preliminary payment rates, proposed as part of the calendar year 2025 gapfill pricing process, are expected to be finalized later this year and will be effective for claims with dates of service on or after January 1, 2025. The proposed rates represent a significant positive development in the Company's efforts to expand access to its advanced cardiovascular testing for Medicare beneficiaries.

Biotech

General

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

Cardio Diagnostics Secures Preliminary Medicare Payment Rates For Epi+Gen CHD And PrecisionCHD, Marking Key Reimbursement Milestone

Barclays analyst Nicholas Campanella maintains CMS Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMS#NYSE">CMS</a>) with a Overweight and raises the price target from $77 to $78.

Barclays Maintains Overweight on CMS Energy, Raises Price Target to $78

ARMK

Howard University Selects Aramark Collegiate Hospitality To Implement Transformative New Campus Dining Vision Called Howard University Hospitality

<a href="https://www.federalreserve.gov/newsevents/speech/powell20250722a.htm" title="https://www.federalreserve.gov/newsevents/speech/powell20250722a.htm">https://www.federalreserve.gov/newsevents/speech/powell20250722a.htm</a>

Macro Economic Events

Economics

Federal Reserve

Fed's Powell Says Fed Is A Dynamic Institution, Open To Hearing New Ideas And Feedback On How To Improve Capital Framework For Large Banks; Need Large Banks To Be Free To Compete With One Another, With Nonbanks And With Banks In Other Jurisdictions

FX Super One will be an affordable mass market MPV (multi-purpose vehicle). It offers a spacious, meticulously crafted interior with high-end materials and advanced technology. The FX Super One prioritizes passenger comfort with a host of features including multiple rows, spacious seating, ambient lighting, and premium entertainment systems, to name a few. The Super One is planned to be available with AWD and two powertrain options: battery electric and, at a later date, an AI hybrid extended range (AIHER) configuration. The groundbreaking Faraday X Super One features state of the art technologies and will be built in Hansford, California.&nbsp;
Nature's Miracle has placed a non-binding pre-order of 1,000 FX Super One to be resold to consumers, subject to receiving financing for the purchase. Although the price of the FX Super One has not yet been announced, the total value of this collaboration is estimated to be up to $100 million. Delivery of the FX Super One is expected to begin by the end of 2025 and go into 2026. Hydroman Electric Corporation, a subsidiary of Nature's Miracle Holding Inc., will distribute the vehicle to consumers. In addition, Nature's Miracle has entered into a co-creation agreement with Faraday Future to facilitate brand exposure among a diverse range of audiences, including high-net-worth individuals, influencers and opinion leaders.

Contracts

Faraday Future Intelligent Electric Inc. - Class A Common Stock

FFAI

Nature's Miracle Holding Announces It Has Placed A Non-Binding Pre-Order Of 1,000 FX Super One MPVs With Faraday Future Intelligent Electric In A Deal Estimated Up To $100M

AGYS

Agilysys shares are trading lower following a Q1 adjusted EPS miss.

Caris Life Sciences Publishes Original Data In New England Journal of Medicine On Recent Findings On Tumor-Infiltrating Clonal Hematopoiesis

Installation and Commissioning Activities Commenced with Treatment of Six PFAS-Impacted Waste Streams to Begin in August
ESTCP will Demonstrate Treatment Options for DoD Installations Impacted by Hazardous Chemicals Found in Firefighting Foams, Industrial Processes, and Contaminated Water Sources
DURHAM, N.C., July 22, 2025 (GLOBE NEWSWIRE) -- 374Water Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCWO#NASDAQ">SCWO</a>) ("374Water") (the "Company"), a global leader in organic waste destruction technology and services for the municipal, federal, and industrial markets, today announced the successful mobilization and delivery of its AirSCWO 6 System for a series of commercial-scale demonstrations at Clean Earth's Detroit, MI facility as part of a previously announced Department of Defense ("DoD") project.
In February, <a href="https://www.globenewswire.com/Tracker?data=BCv6MUMJBnys6gxdH5zhaWnpXdvLRXek13bGL9P8VUj3boB9r6FOHQ6MHbpvwBX9jcX7fVgjP_HMxSda1YkAXZaL5-65cLave55C1AKJcccUHDEIiu7FD2w6Ss8YqRnboKdVYTmcLExkxknv3L0VLRHZF83dCC4CJocpCwrf1blv6ND-xNd4DKUFAwaBswRBFti0ivN5Ym5C0wfMCIBFwjk48kL_4CYe3U53UNyIw3G8Tb5XmP6_DRsCPP59uTDSdQL9WrQC1D4hGqGb42F1UMMqYa9Zmb51oygR57lxMNg=">374Water announced</a> its participation in a highly anticipated DoD project, led by the Defense Innovation Unit ("DIU"), that is evaluating commercial-scale technology solutions to destroy per- and polyfluoroalkyl ("PFAS") contaminated wastes. The DIU is focused on accelerating the adoption of waste destruction technologies to solve operational challenges at speed and scale, and awarding meaningful contracts to companies offering solutions to national security challenges. The demonstration represents a collaboration between the DoD Environmental Security Technology Certification Program ("ESTCP") and the DIU.

SCWO

374Water Begins Commissioning Of AirSCWO 6 System For DoD Project To Treat PFAS-Contaminated Waste At Detroit Facility

Benchmark analyst Todd Brooks maintains Domino's Pizza (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) with a Buy and raises the price target from $535 to $540.

Benchmark Maintains Buy on Domino's Pizza, Raises Price Target to $540

Polyrizon Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) ("Polyrizon" or the "Company"), a biotechnology company focusing on the development of intranasal products, today announced encouraging preclinical results supporting the performance of its PL-14 Allergy Blocker, part of its proprietary&nbsp;Capture &amp; Contain (C&amp;C) platform. The study, conducted in collaboration with the University of Parma (Italy), demonstrated targeted deposition in the nasal vestibule—the key anatomical site for early allergen contact—reinforcing the product's potential as a barrier-forming treatment for allergic rhinitis.
The evaluation was led by Professor Fabio Sonvico from the Department of Food and Drug at the University of Parma, a leading authority in intranasal and pulmonary drug delivery and a member of Polyrizon's Scientific Advisory Board. Using a validated silicone-based human nasal cast and fluorescein-labeled imaging, the study assessed the spray deposition profile of PL-14 when administered under clinically relevant conditions.
The results revealed that the PL-14 formulation achieved over 60% deposition in the nasal vestibule, the first physiological region exposed to airborne allergens. This targeted delivery is critical for effectively blocking allergen contact with the nasal mucosa, supporting the mechanism of action of PL-14 as a physical barrier product designed to capture and contain environmental allergens before they trigger an immune response.

PLRZ

Polyrizon Reports Preclinical Results For PL-14 Allergy Blocker, Showing Over 60% Targeted Nasal Deposition

Northrop Grumman shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 adjusted EPS guidance.

<a href="https://www.globenewswire.com/Tracker?data=7QcIih6QR0fXrjfhTBIUfZm6y_NUwwj2cLv_AW4RXOylPe7Zp63azCXQbuD6NIKehjWwxa8PoJ7pHyMDMakJj-46DE9tAptf03AGsHpsUwY=">Autonomix Medical, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise (or prepayment of the exercise price) of certain outstanding warrants to purchase up to an aggregate of 1,477,596 shares of common stock of the Company originally issued in November 2024 at a reduced exercise price of $1.723 per share. The shares of common stock issuable upon exercise of the outstanding warrants are registered pursuant to an effective registration statement on Form S-1 (File No. 333-282940). The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $2.5 million, before deducting placement agent fees.

Comments

iShares Ethereum Trust - iShares Ethereum Trust ETF

Intérêt court

iShares Ethereum Trust - iShares Ethereum Trust ETF (NASDAQ:ETHA) Stock, Rapport sur les intérêts à découvert

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL